Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 20, 2024
Discovery & Translation

Science Spotlight: A new obesity target may avoid nausea, muscle loss

BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Oct 9, 2024
Distillery Therapeutics

Targeting PRMT3 for HCC antitumor immunity

BioCentury | Aug 1, 2024
Distillery Therapeutics

Inhibiting USP8 for cGAS-mediated autoimmune diseases

BioCentury | Mar 5, 2024
Discovery & Translation

Distillery spotlight: new Alzheimer’s mechanisms from academia

BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease 
BioCentury | Jun 7, 2023
Data Byte

Translational spotlight on immuno-oncology innovation

Mechanisms in BioCentury’s Distillery extend beyond checkpoints
BioCentury | May 5, 2023
Discovery & Translation

J&J’s fusion protein for Staph infection; plus cGAS for Alzheimer’s and more

BioCentury’s roundup of translational news
BioCentury | Dec 7, 2022
Distillery Therapeutics

cGAS-activating nanoassemblies for solid tumors

BioCentury | Sep 29, 2022
Deals

In NLRP3 deal with Novo, Ventus fences off some indications for itself

‘Pragmatic’ deal gives Novo set of cardiometabolic, kidney and liver diseases, while Versant-backed Ventus keeps indications within biotech’s scope
BioCentury | Apr 14, 2022
Product Development

DDR combos on the horizon at AACR22

The first clinical data for a PARP1-selective inhibitor and deeper profiles of ATR-targeting agents suggest combinations will shape the field’s next act
BioCentury | Feb 11, 2022
Distillery Therapeutics

STING inhibition for COVID-19 immunopathology

Items per page:
1 - 10 of 36